SG Americas Securities LLC Acquires 265,558 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

SG Americas Securities LLC lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 16,153.2% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 267,202 shares of the medical research company's stock after purchasing an additional 265,558 shares during the quarter. SG Americas Securities LLC owned approximately 0.54% of Charles River Laboratories International worth $40,219,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Rothschild Investment LLC lifted its position in Charles River Laboratories International by 480.0% during the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after acquiring an additional 144 shares during the period. Optiver Holding B.V. purchased a new position in Charles River Laboratories International during the fourth quarter worth $37,000. GeoWealth Management LLC increased its position in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock worth $46,000 after buying an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $48,000. Finally, Tortoise Investment Management LLC grew its position in shares of Charles River Laboratories International by 77.7% in the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after purchasing an additional 115 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares in the company, valued at approximately $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.30% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CRL shares. JPMorgan Chase & Co. reduced their price objective on Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price for the company in a research report on Thursday, May 8th. Barclays raised their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 8th. Finally, TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Trading Down 0.0%

Shares of CRL stock traded down $0.02 on Friday, hitting $151.88. 145,422 shares of the company's stock traded hands, compared to its average volume of 998,022. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $254.15. The company's fifty day simple moving average is $128.53 and its 200 day simple moving average is $157.72. The stock has a market capitalization of $7.46 billion, a price-to-earnings ratio of 1,012.41, a P/E/G ratio of 4.54 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.27 EPS. Equities analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).